

## Facile Synthesis of Tilmicosin and Tylosin Related Haptens for Use as Protein Conjugates

LAWRENCE C. CREEMER<sup>a</sup>, ROSS C. BEIER<sup>b,\*</sup> and DOUGLAS E. KIEHL<sup>a</sup>

<sup>a</sup> ELANCO Animal Health R&D,  
2001 West Main St., Greenfield, IN 46140-0708

<sup>b</sup> Southern Plains Agricultural Research Center, Agricultural Research Service, U.S. Department of Agriculture,  
2881 F & B Road, College Station, TX 77845-4988

(Received for publication January 20, 2003)

Synthesis is described for the haptens 23-demycinosyl-23-deoxy-23-(3-aminoprop-1-yl)-aminotilmicosin (**6**) from 5-*O*-mycaminosyltylonolide (OMT) and for 23-demycinosyl-23-deoxy-23-(3-aminoprop-1-yl)-amino-20-dihydrotylosin (**10**) from demycinosyltylosin (DMT), respectively. The mild reaction conditions used to synthesize the second hapten, DMT derivative **10**, were necessary to overcome instabilities and acid lability of DMT. The haptens synthesized here may be further used to produce protein conjugates useful in developing antibodies against the antibiotics tilmicosin and tylosin.

Tilmicosin (**1**, Fig. 1) is a semi-synthetic macrolide antibiotic approved for veterinary use in the U.S. for cattle, swine, and poultry to combat respiratory disease. It also is used with sheep in various areas of the world. Tilmicosin (**1**) is derived from the macrolide antibiotic tylosin (**2**, Fig. 1), which is produced by *Streptomyces fradiae*. The synthesis of **1** from **2** has been described<sup>1,2</sup>. Most antimicrobial agents have limited ability for cellular penetration, but **1** was shown to accumulate in bovine lung tissue<sup>3</sup>. To investigate potential tissue binding sites of these molecules, it would be advantageous to produce monoclonal antibodies specific for **1** and **2**.

Previous attempts have been made to produce antibodies to these macrolides. JACKMAN *et al.* reported preparation of polyclonal antibodies against desmycosin, conjugated through the C20 aldehyde group, for use in determining residues of **1** in feeds and tissues<sup>4</sup>. SILVERLIGHT *et al.* reported that such polyclonal antibodies had 96% cross-reactivity with **2**<sup>5</sup>. WICKER *et al.* reported the use of polyclonal antibodies to **2** in a fluorescence immunoassay for detecting **2** in premix and feeds<sup>6</sup>. The antibodies produced to **2** also cross-reacted with **1**. YAO and MAHONEY produced polyclonal antibodies to 23-deoxy-23-amino-OMT; however, these antibodies demonstrated reactivity

with 12-, 14-, and 16-membered macrolides possessing amino-substituted sugar moieties, regardless of the presence of neutral sugar residues<sup>7</sup>.


For our experimental purposes, we required monoclonal antibodies that had high specificity. In order to develop antibodies specific for tilmicosin and tylosin, protein conjugates of derivatives **1** and **2** were required that would present immunologically unique portions of the molecules to the immune system. Therefore, the C20 aldehyde group would not be a good choice for the linkage site. Rather, we considered the C23 position to be a good linkage site that would present the best structural differences of **1** and **2** to the immune system. The selection of antibodies with the best specificity may then be accomplished through the monoclonal screening process.

We expected that the synthesis of analogues of **1** and **2** containing 1,3-diaminopropane linker arms would provide suitable haptens. The amino group was selected since it can be utilized with a number of standard synthetic strategies to produce protein conjugates suitable for antibody production, whereas the linker length also provides sufficient spacing to result in favorable antibody production. This paper describes the synthesis of 23-demycinosyl-23-deoxy-23-(3-aminoprop-1-yl)-

\* Corresponding author: RCBeier@ffsru.tamu.edu



Scheme 1. Synthesis of 23-demycinosyl-23-deoxy-23-(3-aminoprop-1-yl)-aminotilmicosin (**6**) from OMT (**3**).



Scheme 2. Synthesis of 23-demycinosyl-23-deoxy-23-(3-aminoprop-1-yl)-amino-20-dihydrotylosin (**10**) from DMT (**7**).






Fig. 2. ESI-TOF-MS of DMT iodination reaction products.

Fig. 3. ESI-TOF-MS of crude product **10**.

purified due both to the reactivity of the C20 aldehyde group and the acid lability of the linkage between the two carbohydrate groups. Rather, reducing it to the alcohol immediately deactivated the aldehyde group at C20 of **8**<sup>11</sup>. Thus, product **8** was reacted with sodium borohydride in isopropanol and water to form the alcohol **9** according to

the method of KIRST *et al.*<sup>11</sup>). Upon evaporation of CH<sub>2</sub>Cl<sub>2</sub> from the product **9**, a glass formed, which was directly used in the next reaction. The desired hapten **10** was achieved in overall 11% yield from **7** via an iodide displacement reaction by employing a five-fold excess of 1,3-diaminopropane in ACN in the presence of potassium

carbonate, a modified method of KIRST *et al.*<sup>9)</sup> The ESI-TOF-MS of the crude product **10** is shown in Fig. 3.

Since the resulting two haptens, **6** and **10** contain an NH<sub>2</sub> linker arm, they can be conjugated to proteins under a number of commonly used conditions. The length of the linker arm is appropriate for favorable recognition and antibody production by the immune system. Experiments to this end are on-going.

## Experimental

### General Analytical Methods

NMR data were acquired on a Bruker Avance 500 NMR spectrometer, and the following experiments were performed: 1D <sup>1</sup>H, 1D <sup>13</sup>C, <sup>1</sup>H-<sup>1</sup>H 2D COSY, <sup>1</sup>H-<sup>1</sup>H 2D ROESY, <sup>1</sup>H-<sup>1</sup>H 2D TOCSY, <sup>1</sup>H-<sup>13</sup>C 2D g-HSQC, and <sup>1</sup>H-<sup>13</sup>C 2D g-HMBC. Positive ion electrospray ionization (ESI) mass spectra were acquired using either a Micromass Quattro LC mass spectrometer or a Micromass LCT time-of-flight mass spectrometer. Most of the chemicals were purchased from Aldrich Chemical Company or prepared by the Eli Lilly and Company Natural Products Division and were used without further purification. Semi-preparative high performance liquid chromatography (HPLC) was accomplished using a Supelcosil LC-18-DB Semi-Prep 25 cm×10 mm ID column by Supelco, Inc. (Bellefonte, PA) with the solvent system of ACN/MeOH/1/2% NH<sub>4</sub>OAc buffer (56<sup>1</sup>/<sub>2</sub>:41:2<sup>1</sup>/<sub>2</sub>, v/v/v) at 4.75 ml/minute using Waters M-6000 pumps and a Waters 996 photodiode Array Detector (Waters Corporation, Milford, MA). Flash chromatography was carried out using silica gel EM Science Kielselgel 60 (230~400 mesh ASTM).

### 23-Demycinosyl-tilmicosin (**4**)

OMT (**3**; 3.0 g, 5.0 mmol) was dissolved in anhydrous methanol (30 ml). 3,5-dimethylpiperidine (1.3 ml, 9.8 mmol) was added followed by sodium cyanoborohydride (0.64 g, 10.1 mmol). This mixture was allowed to stir at room temperature for 24 hours and was monitored by HPLC. The mixture was then diluted with EtOAc and extracted with commercially available pH 4 buffer (3 times). The buffer was brought to pH 12 with a 50% NaOH soln. The aqueous layer was then extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 times). The CH<sub>2</sub>Cl<sub>2</sub> layers were combined, washed with brine, and then dried over anhydrous sodium sulfate. The soln was then evaporated at room temperature under reduced pressure to give **4** as a pale yellow solid (2.7 g; 78% yield). This material was used without further purification.

### 23-Demycinosyl-23-deoxy-23-iodo-tilmicosin (**5**)

23-Demycinosyl-tilmicosin (**4**; 7.8 g, 11.2 mmol) was dissolved in anhydrous THF (40 ml). Triphenylphosphine (4.4 g, 16.8 mmol) was added to this soln followed by pyridine (10 ml), and the mixture was cooled on an ice bath. Iodine (4.2 g, 16.5 mmol) in anhydrous THF (15 ml) was added drop-wise to the ice-cold soln. When the addition was complete the mixture was allowed to stir at room temperature for 18 hours. The reaction was then quenched by addition of 5% sodium thiosulfate soln drop-wise until the iodine color dissipated. The mixture was then diluted with CH<sub>2</sub>Cl<sub>2</sub> and washed with satd NaHCO<sub>3</sub>. The CH<sub>2</sub>Cl<sub>2</sub> was then washed with brine, dried over anhydrous sodium sulfate and evaporated at room temperature under reduced pressure to a small volume. This material was diluted with fresh CH<sub>2</sub>Cl<sub>2</sub> and the resulting soln was extracted with 1 N HCl. The aqueous soln was made alkaline with 5 N NaOH and reextracted with EtOAc. The EtOAc soln was washed with brine, dried over anhydrous sodium sulfate and evaporated at room temperature under reduced pressure. This gave **5** as a light yellow solid (2.7 g, 30% yield). This material was used without further purification; HPLC showed that the product was approximately 68% pure.

### 23-Demycinosyl-23-deoxy-23-(3-aminoprop-1-yl)-aminotilmicosin (**6**)

Crude 23-demycinosyl-23-deoxy-23-iodo-tilmicosin (**5**; 3.0 g, 1.9 mmol) was dissolved in ACN (50 ml). Commercially available 1,3-diaminopropane (780 μl, 9.4 mmol) was added to this soln and the mixture was stirred at 60°C for 19 hours. The reaction mixture was cooled to room temperature and evaporated under reduced pressure. The crude product was taken up between EtOAc and freshly prepared pH 4 buffer (Note: avoid commercial buffers containing formaldehyde). The phases were separated and the aqueous phase was washed with fresh EtOAc until no more UV active material was removed. The buffer was brought to pH 12 with 5 N NaOH and reextracted with CH<sub>2</sub>Cl<sub>2</sub>. The CH<sub>2</sub>Cl<sub>2</sub> was dried over anhydrous sodium sulfate and evaporated at room temperature at reduced pressure giving **6** (0.84 g, 60% yield based on purity of **5**). To obtain ultra pure material **6** (120 mg) was purified by semi-prep HPLC, as described in the general analytical methods section. The collected material was diluted with pH 10 NaHCO<sub>3</sub> buffer (75 ml), and extracted with fresh CH<sub>2</sub>Cl<sub>2</sub> (3×30 ml). The combined CH<sub>2</sub>Cl<sub>2</sub> layers were dried over sodium sulfate, filtered through Whatman #41 filter paper, and evaporated under vacuum at room temperature to obtain 54 mg **6** at greater than 99% purity. ESI-MS *m/z* 751.6 (M+1)<sup>+</sup>; <sup>1</sup>H- and <sup>13</sup>C-

Table 1.  $^1\text{H}$ - and  $^{13}\text{C}$ -NMR data for product **6**.

Position	$^{13}\text{C}$	$^1\text{H}$	Position	$^{13}\text{C}$	$^1\text{H}$
1	173.03	—	23	51.25	2.75, 2.69
2	40.17	2.30, 1.97	24	—	—
3	67.09	3.78	25	49.10	2.66
4	42.78	1.59	26	N.A.	N.A.
5	80.00	3.60	27	N.A.	N.A.
6	32.64	1.63	28	—	—
7	34.60	1.74, 1.48	1'	105.58	4.27
8	45.85	2.60	2'	71.25	3.37
9	203.72	—	3'	71.66	2.37
10	119.39	6.50	4'	71.82	3.08
11	148.12	7.21	5'	73.92	3.31
12	135.80	—	6'	18.24	1.21
13	145.14	5.71	7', 8'	42.04	2.51
14	45.94	2.93	1''	—	—
15	75.80	4.76	2''	59.76	2.87, 1.06
16	25.93	1.88, 1.60	3''	30.87	1.83
17	9.97	0.92	4''	43.48	1.70, 0.47
18	9.29	0.99	5''	30.66	1.85
19	25.21	1.71	6''	64.38	2.68, 1.41
20	55.40	2.76, 1.99	7''	19.88	0.97
21	17.91	1.19	8''	19.98	0.80
22	13.19	1.85			

N.A. = Not Assigned

NMR data are presented in Table 1.

23-Deoxy-23-(3-aminoprop-1-yl)-amino-20-dihydro-DMT (10)

DMT (**7**; 0.45 g, 0.61 mmol) was dissolved in anhydrous pyridine (3 ml). Triphenylphosphine (0.32 g, 1.2 mmol) was added, followed by 4 Å molecular sieves (pyridine just covered the molecular sieves) and this mixture was stirred for 80 minutes at room temperature under dry argon. The mixture was cooled on an ice bath, and a soln of  $\text{I}_2$  (0.46 g, 1.8 mmol) in anhydrous pyridine (1 ml) was added dropwise *via* a syringe. The mixture, having a noticeable brown

$\text{I}_2$  color, was stirred for 80 minutes in the ice bath and then at room temperature for 1 hour. The mixture was filtered through a double-layered sandwich of Whatman #2 and #41 filter paper with the aid of  $\text{CH}_2\text{Cl}_2$  (40 ml). The filtrate was washed with satd  $\text{NaHCO}_3$  (75 ml), and extracted three successive times with fresh  $\text{CH}_2\text{Cl}_2$  (40 ml,  $2 \times 30$  ml), and the  $\text{CH}_2\text{Cl}_2$  layers were combined. The combined layers were washed with 1 M sodium thiosulfate (80 ml), and the aqueous layer was reextracted with fresh  $\text{CH}_2\text{Cl}_2$  ( $2 \times 30$  ml). The  $\text{CH}_2\text{Cl}_2$  layers were combined, dried over anhydrous sodium sulfate, and evaporated under vacuum at room temperature to afford 23-deoxy-23-iodo-DMT (**8**).

This material was dissolved in 2-propanol (6 ml) and H<sub>2</sub>O (4 ml), and sodium borohydride (5.8 mg, 0.15 mmol) was added in small portions. Forty-five minutes after the addition was complete, the pH of the reaction mixture was adjusted to 7.0 by addition of 0.1 N H<sub>2</sub>SO<sub>4</sub>. The neutralized soln was evaporated to a small volume to remove the isopropanol, and then treated with satd NaHCO<sub>3</sub> (30 ml). The mixture was extracted with fresh CH<sub>2</sub>Cl<sub>2</sub> (3×20 ml), and the combined CH<sub>2</sub>Cl<sub>2</sub> extracts were washed with satd NaCl (35 ml), then dried over anhydrous sodium sulfate, filtered, and evaporated under vacuum at room temperature to give 23-deoxy-23-iodo-20-dihydro-DMT (**9**). This material was dissolved in ACN (5 ml) in a 10 ml Reacti-vial (Pierce, Rockford, IL). Potassium carbonate (0.17 g, 1.2 mmol) was added to the reaction mixture, followed by 1,3-diaminopropane (1.7 mmol, 0.14 ml). The reaction mixture was stirred at 60°C, and the course of the reaction was followed by TLC on HPTLC-Fertigplatten, Kieselgel 60 F<sub>254</sub> with a concentration zone (EM Science, Gibbstown, NJ) using EtOAc/EtOH (80:20, v/v). After 24 hours at 60°C, the mixture was cooled to room temperature, and filtered through a sandwich filter of Whatman #2 and #41 to remove the potassium carbonate. CH<sub>2</sub>Cl<sub>2</sub> was used to aid filtration. The filtrate was evaporated under vacuum at room temperature. The residue was taken up with fresh CH<sub>2</sub>Cl<sub>2</sub> (40 ml) and washed with satd NaHCO<sub>3</sub> (75 ml). The NaHCO<sub>3</sub> layer was extracted with fresh CH<sub>2</sub>Cl<sub>2</sub> (2×30 ml), and the combined CH<sub>2</sub>Cl<sub>2</sub> layers were extracted with pH 3.0 buffer (100 ml). The buffer layer was then washed with fresh CH<sub>2</sub>Cl<sub>2</sub> (4×40 ml). The pH was raised to 10 with 4 N NaOH, extracted with fresh CH<sub>2</sub>Cl<sub>2</sub> (40 ml), twice more with fresh CH<sub>2</sub>Cl<sub>2</sub> (30 ml), and the combined CH<sub>2</sub>Cl<sub>2</sub> layers were dried over anhydrous sodium sulfate, filtered, and evaporated under vacuum at room temperature to afford 51 mg of 23-deoxy-23-(3-aminoprop-1-yl)-amino-20-dihydro-DMT (**10**) in an overall 11% yield from DMT (**7**). ESI-MS *m/z* 800.5 (M+1)<sup>+</sup> (base), 744.5 (base-H<sub>2</sub>NCH<sub>2</sub>-CH=CH)<sup>+</sup> (Fig. 3).

#### Acknowledgement

The Authors would like to thank the Fermentation Products Division of Eli Lilly and Company for supplying starting materials. The Authors also would like to thank Mr. ROSS A. JOHNSON for NMR support. The work described here was completed under CRADA No. 58-3K95-8-687 between the USDA, Agricultural Research Service, 2881 F&B Road, College Station, TX 77845 and Elanco Animal Health R&D, a Division of Eli Lilly and Company, 2001 West Main Street, Greenfield, IN 46140.

#### References

- 1) DEBONO, M. & H. A. KIRST: C-20-dihydro-deoxy-(cyclic amino)-derivatives of macrolide antibiotics. U.S. Patent 4,820,695, April 11, 1989
- 2) DEBONO, M.; K. E. WILLARD, H. A. KIRST, J. A. WIND, G. D. CROUSE, E. V. TAO, J. T. VICENZI, F. T. COUNTER, J. L. OTT, E. E. OSE & S. ŌMURA: Synthesis and antimicrobial evaluation of 20-deoxo-20-(3,5-dimethylpiperidin-1-yl)desmycosin (tilmicosin, EL-870) and related cyclic amino derivatives. *J. Antibiotics* 42: 1253~1267, 1989
- 3) SCORNEAUX, B. & T. R. SHRYOCK: Intracellular accumulation, subcellular distribution, and efflux of tilmicosin in bovine mammary, blood, and lung cells. *J. Dairy Sci.* 82(6): 1202~1212, 1999
- 4) JACKMAN, R.; Y. I. SPENCER, J. J. SILVERLIGHT, S. A. MARSH & P. J. BELLERBY: Development of antibodies to tilmicosin and their use in the immunolocalization of the antibiotic in porcine lung tissue. *J. Vet. Pharmacol. Therap.* 20(Suppl. 1): 131~132, 1997
- 5) SILVERLIGHT, J. J.; A. J. BROWN & R. JACKMAN: Antisera to tilmicosin for use in ELISA and for immunohistochemistry. *Food Agric. Immunol.* 11(4): 321~328, 1999
- 6) WICKER, A. L.; D. H. MOWREY, D. J. SWEENEY, M. R. COLEMAN, D. K. MORRIS & C. L. BROCKUS: Particle concentration fluorescence immunoassay for determination of tylosin in premix, feeds, and liquid feed supplement: Comparison with turbidimetric assay. *J. AOAC Internat.* 77(5): 1083~1095, 1994
- 7) YAO, R. C. & D. F. MAHONEY: Enzyme immunoassay for macrolide antibiotics: Characterization of an antibody to 23-amino-*O*-mycaminosyltylonolide. *Appl. Environ. Microbiol.* 55(6): 1507~1511, 1989
- 8) KIRST, H. A.; K. E. WILLARD, M. DEBONO, J. E. TOTH, B. A. TRUEDELL, J. P. LEEDS, J. L. OTT, A. M. FELTY-DUCKWORTH, F. T. COUNTER, E. E. OSE, G. D. CROUSE, J. M. TUSTIN & S. ŌMURA: Structure-activity studies of 20-deoxo-20-amino derivatives of tylosin-related macrolides. *J. Antibiotics* 42: 1673~1683, 1989
- 9) KIRST, H. A.; J. E. TOTH, J. A. WIND, M. DEBONO, K. E. WILLARD, R. M. MOLLOY, J. W. PASCHAL, J. L. OTT, A. M. FELTY-DUCKWORTH & F. T. COUNTER: Synthesis, antimicrobial evaluation and structure-activity relationships within 23-modified derivatives of 5-*O*-mycaminosyltylonolide. *J. Antibiotics* 40: 823~842, 1987
- 10) SAKAMOTO, S.; T. TSUCHIYA, T. MIYAKE, A. TANAKA & S. UMEZAWA: Syntheses of 23-dialkylamino-23-deoxydemycinosyltylosins and conformational study of mycaminosyl tylonolide by nuclear overhauser difference spectroscopy. *Bull. Chem. Soc. Jpn.* 57(12): 3536~3542, 1984
- 11) KIRST, H. A.; J. E. TOTH, M. DEBONO, K. E. WILLARD, B. A. TRUEDELL, J. L. OTT, F. T. COUNTER, A. M. FELTY-DUCKWORTH & R. S. PEKAREK: Synthesis and evaluation of tylosin-related macrolides modified at the aldehyde function: A new series of orally effective antibiotics. *J. Med. Chem.* 31(8): 1631~1641, 1988